Anavex Life Sciences Corp (AVXL)

[falconer66a]

The only thing that counts?

First to market in partnership with Acadia will be a huge upside. They’ll be first to market with a strong partner by at least a year or two.

Yea, that’s the first question I ask my neurologist for my several CNS debilities. “Doc, but was this drug you want me to take first in the market for my condition? If it wasn’t, I’m not going to take it. I learned from an expert on a stock message board that unless a drug is first to market, it’s no good.”

Sure, first to market is the prime determiner of efficacy and therapeutic usage.

Tell us more. Looks like Aduhelm has the Alzheimer’s market wrapped up — except that Aricept was first to market. Anavex, with blarcamesine, hasn’t got a chance, does it? Missling should have known better and never have mentioned Alzheimer’s. Anavex, with blarcamesine; last to market. No chance of success. Both doctors and patients will be turning away from blarcamesine. Clinical results count for nothing. First to market is all that counts.

How the drug market really works can be learned here, can’t it? Sure. Tomorrow, I’ll consider selling my AVXL position.